The short version of peptide analog fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-04 and is reviewed periodically as new material appears.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
== History == Relief Therapeutics was founded in 2013 by Gael Hédou with the aim of developing new treatments for diseases with high unmet needs. The company today considers itself the successor to Mondobiotech, which was founded in 2000 by Fabio Cavalli and Dorian Bevec. Mondobiotech began research into Vasoactive intestinal peptide (VIP), a naturally occurring substance in humans that was first identified in the 1970s. They were granted US and European patents for a synthetic version of VIP known as aviptadil in 2006. On June 23, 2013, Mondobiotech merged with Italian pharmaceutical company Pierrel Research International to form a new Contract research organization known as Therametrics. On July 14, 2016, Therametrics merged with Relief Therapeutics to form Relief Therapeutics Holdings AG, which inherited all patents related to aviptadil.
Fripp was dissatisfied with the quality of the new music being developed by the band, and longstanding friction between himself and Bruford resurfaced. The resulting atmosphere and the lack of workable material almost broke the band up altogether. Instead, the six members opted to work in four smaller groups (or "fraKctalisations", as Fripp called them) known as ProjeKcts. This enabled the group to continue developing ideas and searching for a new direction without the practical difficulty and expense of convening all six musicians at once. From late 1997 to early 1999, ProjeKct One (Fripp, Bruford, Levin, Gunn), ProjeKct Two (Fripp, Belew, Gunn), ProjeKct Three (Fripp, Gunn, Mastelotto), and ProjeKct Four (Fripp, Levin, Gunn, Mastelotto) played live in the United States and the United Kingdom, with recordings from these performances released on The ProjeKcts box set in 1999. These largely-improvised recordings, along with ProjeKct Two's 1998 studio album Space Groove, showed influences including jazz, industrial, techno and drum and bass. Music critic J. D. Considine considered the ProjeKcts' work "frequently astonishing" but lacking in melody. The four live performances of ProjeKct One in December 1997 would be Bruford's last involvement with King Crimson.
Education and health are provided mainly by member states, but shaped by common minimum standards in EU law. In the case of education, the European Social Charter, like the Universal Declaration, the International Bill of Human Rights, say that "everyone" has the right to education, and that primary, secondary and higher education should be made "free", for instance "by reducing or abolishing any fees or charges" and "granting financial assistance". While the history of education was confined to a wealth elite, today most member states have tuition free university. There are no common rules for university finance or governance, although there is a right to free movement and universities have voluntarily harmonised standards. In 1987, the Erasmus Programme was created to fund students to study in other countries, and with a budget of €30 billion from 2021 to 2027. From 1999, the Bologna Declaration and Process led to the creation of the European Higher Education Area where member state universities adopted a common degree structure (bachelor, master, and doctoral degree) with a goal to have similar expectations in learning outcomes. Member states may not impose different fees on students from other member states or limit their numbers, and this appears to have worked even without a system for countries to reimburse one another if costs differ widely. However, if member states have grants or student loans, R (Bidar) v London Borough of Ealing held there may be a minimum residency requirement, such as three years.
Sources: en.wikipedia.org
A lot of effort has been put into controlling cell selectivity. For example, attempts have been made to modify and optimize the physicochemical parameters of the peptides to control the selectivities, including net charge, helicity, hydrophobicity per residue (H), hydrophobic moment (μ) and the angle subtended by the positively charged polar helix face (Φ). Other mechanisms like the introduction of D-amino acids and fluorinated amino acids in the hydrophobic phase are believed to break the secondary structure and thus reduce hydrophobic interaction with mammalian cells. It has also been found that Pro→Nlys substitution in Pro-containing β-turn antimicrobial peptides was a promising strategy for the design of new small bacterial cell-selective antimicrobial peptides with intracellular mechanisms of action. It has been suggested that direct attachment of magainin to the substrate surface decreased nonspecific cell binding and led to improved detection limit for bacterial cells such as Salmonella and E. coli.
Plutonium recovered from LWR spent fuel, while not weapons grade, can be used to produce nuclear weapons at all levels of sophistication, though in simple designs it may produce only a fizzle yield. Weapons made with reactor-grade plutonium would require special cooling to keep them in storage and ready for use. A 1962 test at the U.S. Nevada National Security Site (then known as the Nevada Proving Grounds) used non-weapons-grade plutonium produced in a Magnox reactor in the United Kingdom. The plutonium used was provided to the United States under the 1958 US–UK Mutual Defence Agreement. Its isotopic composition has not been disclosed, other than the description reactor grade, and it has not been disclosed which definition was used in describing the material this way. The plutonium was apparently sourced from the Magnox reactors at Calder Hall or Chapelcross. The content of Pu-239 in material used for the 1962 test was not disclosed, but has been inferred to have been at least 85%, much higher than typical spent fuel from currently operating reactors. Occasionally, low-burnup spent fuel has been produced by a commercial LWR when an incident such as a fuel cladding failure has required early refuelling. If the period of irradiation has been sufficiently short, this spent fuel could be reprocessed to produce weapons grade plutonium.
=== Diabetes === Empagliflozin is indicated in adults with type 2 diabetes and established cardiovascular disease to reduce the risk of cardiovascular death; and as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. In June 2023, the US Food and Drug Administration (FDA) expanded the indication, as an addition to diet and exercise, to improve blood sugar control in children 10 years and older with type 2 diabetes. Empagliflozin has shown beneficial effects on cardiovascular morbidity and mortality in patients with type 2 diabetes. Additionally, large-scale randomised controlled trials have demonstrated that empagliflozin decreases heart failure hospitalisations and cardiovascular mortality in adults with heart failure, whether they have reduced, mid-range, or preserved left ventricular ejection fraction and regardless of type 2 diabetes status. There is evidence from high quality studies that empagliflozin can also help to slow the rate of kidney function decline. Irrespective of diabetes status, benefit was observed in those with mild, moderate or severe loss of kidney function. People started on empagliflozin may first see a decrease in kidney function before their glomerular filtration rate stabilises. Greatest benefit was demonstrated in those who had severe loss of kidney function, higher risk of kidney function worsening and background of diabetes. Empagliflozin is also available as the fixed-dose combinations empagliflozin/linagliptin, empagliflozin/metformin, and empagliflozin/linagliptin/metformin.
=== Fruits === Fruits with a wide variety of structural origins have converged to become edible. Apples are pomes with five carpels; their accessory tissues form the apple's core, surrounded by structures from outside the botanical fruit, the receptacle or hypanthium. Other edible fruits include other plant tissues; the fleshy part of a tomato is the walls of the pericarp. This implies convergent evolution under selective pressure, in this case the competition for seed dispersal by animals through consumption of fleshy fruits. Seed dispersal by ants (myrmecochory) has evolved independently more than 100 times, and is present in more than 11,000 plant species. It is one of the most dramatic examples of convergent evolution in biology.
Sources: en.wikipedia.org
=== Spin column === Spin column-based nucleic acid purification is a method of purifying DNA, RNA or plasmid from a sample using a spin column filter. The method is based on the principle of selectively binding nucleic acids to a solid matrix in the spin column, while other contaminants, such as proteins and salts, are washed away. The conditions are then changed to elute the purified nucleic acid off the column using a suitable elution buffer.
is time (unit s). Further simulations and analysis of this equation show that the square root dependence on the time is originated from the decrease of the concentrations near the surface under ideal adsorption conditions. Also, this equation only works for the beginning of the adsorption when a well-behaved concentration gradient forms near the surface. Correction on the reduction of the adsorption area and slowing down of the concentration gradient evolution have to be considered over a longer time. Under real experimental conditions, the flow and the small adsorption area always make the adsorption rate faster than what this equation predicted, and the energy barrier will either accelerate this rate by surface attraction or slow it down by surface repulsion. Thus, the prediction from this equation is often a few to several orders of magnitude away from the experimental results. Under special cases, such as a very small adsorption area on a large surface, and under chemical equilibrium when there is no concentration gradience near the surface, this equation becomes useful to predict the adsorption rate with debatable special care to determine a specific value of
Ukraine claimed that the armored strength of the Russian Southern Group of Forces had decreased "significantly" to 650 tanks, including those damaged or otherwise disabled, and total number of AFVs deployed was "no more than" 1,850 vehicles.
== Mass spectrometry == Radical cations appear prominently in mass spectrometry. When a gas-phase molecule is subjected to electron ionization one electron is abstracted by an electron in the electron beam to create a radical cation M+.. This species represents the molecular ion or parent ion. A typical mass spectrum shows multiple signals because the molecular ion fragments into a complex mixture of ions and uncharged radical species. For example, the methanol radical cation fragments into a methenium cation CH+3 and a hydroxyl radical. In naphthalene the unfragmented radical cation is by far the most prominent peak in the mass spectrum. Secondary species are generated from proton gain (M+1) and proton loss (M-1).
==== Opioid receptors ==== CPA has been found to bind to several of the opioid receptors, including the μ-, δ-, and κ-opioid receptor subtypes. However, this binding is very weak relative to its other actions (IC50 for inhibition of [3H]diprenorphine binding = 1.62 ± 0.33 μM). It has been suggested that activation of opioid receptors might be involved in the sedation that is reportedly sometimes seen with high doses of CPA or in its reported effectiveness in the treatment of cluster headaches.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.